IDO1 and neoplasm: IDO-1-expression in tumor infiltrate was much higher (as compared to tumor cells); for 4 patients IHC-staining was not clearly detectable and of the 433 remaining patients, tumor immune infiltrate was IDO-1- for just 27 patients (6.2%), while 406 patients (93.8%) were IDO-1+.